Cargando…
Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?
Advanced gene and cellular therapies risk a second “valley of death” due to their high costs and low patient population. As these are life‐saving therapies, measures are urgently needed to prevent their withdrawal from the market.[Image: see text]
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900339/ https://www.ncbi.nlm.nih.gov/pubmed/36592141 http://dx.doi.org/10.15252/embr.202256661 |